| bivalirudin versus heparin + GP2b3a inhibitors | |||
| ACUITY (Stone) (bivalirudin alone), 2006 NCT00093158 | bivalirudin alone versus unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor | patients with acute coronary syndromes | open Follow-up duration: 30 days |
| HORIZONS-AMI (Stone), 2008 NCT00433966 | Bivalirudin versus Heparin plus GP IIb/IIIa inhibitor | patients with ST-segment elevation myocardial infarction who presented within 12 hours after the onset of symptoms and who were undergoing primary PCI | open Follow-up duration: 30 days 11 countries |
| REPLACE-2, 2003 | bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI versus heparin plus planned Gp IIb/IIIa blockade | patients undergoing urgent or elective PCI | double blind Follow-up duration: 30 days 9 countries |
| bivalirudin versus UFH | |||
| ARMYDA BIVALVE, | bivalirudin (0.75 mg/kg bolus followed by 1.75 mg/kg per hour during the procedure) versus unfractionated heparin (75 IU/kg) | patients at high bleeding risk (over 75 years of age, diabetes, reduced renal function) scheduled for PCI | |
| BAT (Bittl), 1995 | bivalirudin immediately before angioplasty. versus heparin immediately before angioplasty | patients undergoing urgent angioplasty for unstable or postinfarction angina | double blind Follow-up duration: hospital stay US |
| ISAR-REACT 3, 2008 NCT00262054 | UFH bolus of 140 U/kg versus bivalirudin (bolus of 0.75 mg/kg, followed by infusion of 1.75 mg/kg/hr) | troponin-negative patients undergoing PCI | double blind Follow-up duration: 30 days (mean) |
| REPLACE-1, 2004 | bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/h infusion during the procedure versus heparin (70 U/kg initial bolus) adjusted to ACT of 200 to 300s | patients undergoing elective or urgent revascularization | Follow-up duration: hospital stay (48h min) US |
| bivalirudin versus UFH plus tirofiban | |||
| NAPLES (Tavano), 2009 | bivalirudin monotherapy versus unfractionated heparin plus tirofiban | patients with diabetes mellitus undergoing elective percutaneous coronary intervention | open Follow-up duration: 30 days Italy |
| bivalirudin + eptifibatide versus heparin + GP2b3a inhibitors | |||
| Kleiman, 2002 | bivalirudin + eptifibatide versus heparin + eptifibatide | patients who underwent elective percutaneous coronary intervention | open |
| dalteparin versus UFH | |||
| Natarajan (without antiGp2b3a), 2003 | Dalteparin 100 IU/kg bolus versus UFH 100 IU/kg bolus | Elective or urgent PCI | |
| dalteparin versus UFH + anti Gp2b3a | |||
| Natarajan (+ antiGp2b3a), 2003 | Dalteparin 70 IU/kg bolus + GP IIb/IIIa inhibitorse/p versus UFH 70 IU/kg bolus +GPIIb/IIIa inhibitors | ||
| enoxaparin versus UFH | |||
| ATOLL, 2010 | IV enoxaparin versus UFH | patients undergoing PCI for acute STEMI | open Follow-up duration: 30 days Austria, France, Germany, and US |
| Brieger, | enoxaparin versus unfractionated heparin | patients undergoing percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI) | |
| CRUISE, 2003 | Enoxaparin 0.75 mg/kg bolus versus UFH 60 IU/kg bolus, then titrated to ACT > 200 | Urgent or elective PCI | open Follow-up duration: 2,7 +30 days |
| Drozd, 2001 | Enoxaparin 1 mg/kg bolus versus UFH 100 IU/kg bolus | PCI for stable angina | Follow-up duration: 24hrs, 30 days |
| Dudek, 2000 | Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT > 300 | PCI | Follow-up duration: 3à days |
| Dudek b (enox alone), 2000 | Enoxaparin 1 mg/kg bolus versus UFH titrated to ACT > 300 | PTCA complex lesionsCI | |
| Galeote, 2001 | Enoxaparin 0.75 mg/kg bolus versus UFH 70 U/kg bolus, then titrated to ACT > 200 | PTCA patients with stable/unstable angina or AMI | |
| Rabah, 1999 | Enoxaparin 1 mg/kg bolus versus UFH 10,000 IU bolus, then titrated to ACT > 300 | PCI for stable angina | open |
| STEEPLE, 2006 NCT00077844 | enoxaparin (0.5 or 0.75 mg per kilogram of body weight) versus unfractionated heparin (adjusted for activated clotting time) | elective percutaneous coronary intervention. | open |
| enoxaparin+abciximab versus UFH | |||
| Dubek b (+abciximal), 2001 | Enoxaparin 0.75 mg/kg bolus + abciximab versus UFH titrated to ACT > 300 | ||
| reviparin versus UFH | |||
| REDUCE, 1996 | Reviparin 7,000 IU anti-Xa versus UFH 10,000 IU bolus | PTCA with stable/unstable angina | double blind Follow-up duration: 3 days Europe and Canada |
in first
in second
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
